SGHT · Sight Sciences, Inc.

Summary

Sight Sciences reported Q1 2026 revenue of $19.7 million, up 13% year-over-year, raised full-year 2026 revenue guidance to $83-89 million, and secured $55.4 million in patent damages from Alcon.

Key takeaways

• Total Q1 2026 revenue $19.7M, +13% YoY, driven by Glaucoma $18.3M (+7%) and Dry Eye $1.4M (+244%).
• Gross margin 86%, flat YoY; net loss $13.0M or ($0.24)/share, improved from ($0.28)/share.
• Raised FY2026 revenue guidance to $83-89M (7-15% growth), Glaucoma $77-81M, Dry Eye $6-8M.
• Cash usage $7.0M, down 40% YoY; cash $85.0M as of March 31, 2026.
• U.S. court awarded $55.4M past damages + 10% ongoing royalty on Alcon Hydrus sales, subject to appeal.